In Vivo Cancer Model Development Services
Solutions
Online Inquiry

In Vivo Cancer Model Development Services

Alfa Cytology specializes in providing comprehensive in vivo cancer model development services, aimed at supporting the development of novel cancer therapeutics through the creation and optimization of animal models that accurately mimic human cancer biology.

Overview of In Vivo Cancer Model Research

An in vivo cancer model refers to the use of living organisms, typically rodents, to study the development, progression, and treatment of cancer. These models provide a dynamic and complex environment where tumor cells interact with the host's immune system, stroma, and other tissues. This interaction is critical for understanding the intricacies of cancer biology and the response to therapies, which cannot be fully replicated in vitro.

Fig. 1 Schematic representation of the generation of common preclinical mouse cancer models.Fig.1 Common in vivo preclinical mouse cancer models. (Sailer, V., et al., 2023)

In vivo cancer models help elucidate the mechanisms of tumor growth and metastasis, evaluate the pharmacokinetics and pharmacodynamics of new drugs, and assess the efficacy and toxicity of potential treatments in a living system. Additionally, in vivo models also allow the testing of patient-derived xenografts (PDXs), which are created by implanting human tumor tissues into immunodeficient mice. This method enables researchers to study individual patient tumors in a controlled environment and tailor therapies accordingly.

Our Services

With a well-established technology platform of the tumor microenvironment center, Alfa Cytology provides you with a combined service of existing models, custom models and novel model development, which is designed to provide efficient, reproducible, and validated in vivo cancer models to accurately study specific cancer types, genetic profiles, and therapeutic responses.

Our In Vivo Cancer Model Development Types

To support the diverse needs of cancer researchers, we are committed to offering a wide range of in vivo cancer models including, but not limited to, the following types.

Our Cutting-Edge Technologies

Alfa Cytology employs a variety of cutting-edge technologies to enhance the development and utilization of in vivo cancer models. These state-of-the-art tools and methods ensure the accuracy, reliability and reproducibility of results.

  • CRISPR/Cas9 Gene Editing
  • Micro CT and MRI Imaging
  • Single-cell RNA Sequencing (scRNA-seq)
  • Intravital Microscopy
  • AI and Machine Learning
  • Next-Generation Sequencing (NGS)
  • Flow Cytometry and Mass Cytometry
  • 3D Bioprinting

Workflow of Model Customization Service

Feasibility Analysis and Planning

Feasibility Analysis and Planning

Review the literature and existing models to develop a detailed project plan.

Model Selection and Genetic Engineering

Model Selection and Genetic Engineering

Select the most appropriate base model and introduce specific genetic modifications.

Tumor Implantation and Model Establishment

Tumor Implantation and Model Establishment

Preparation of tumor cells and their precise implantation into selected animal models.

Model Characterization and Validation

Model Characterization and Validation

Perform tumor phenotyping and genotyping, imaging and monitoring to validate models.

Therapeutic Testing and Optimization

Therapeutic Testing and Optimization

Test customized models for response to therapeutic agents and optimize dosage and dosing regimens.

Alfa Cytology provides comprehensive solutions to address key challenges encountered in the field of cancer therapy development. With extensive experience in a wide range of cancer models and expertise in tumors and microenvironments, we are committed to providing our clients with the most accurate in vivo cancer models to meet their precise needs. For inquiries or to learn more about how we can support your cancer research program, please contact us.

Reference

  1. Sailer, V., et al.; (2023). Experimental in vitro, ex vivo and in vivo models in prostate cancer research. Nature Reviews Urology, 20(3), 158-178.

For research use only.